This trial is evaluating whether Adavosertib will improve 2 primary outcomes and 5 other outcomes in patients with Gliosarcoma. Measurement will happen over the course of Baseline to day 8.
This trial requires 46 total participants across 1 different treatment group
This trial involves a single treatment. Adavosertib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"An estimated 0.05 per 10,000 people in the U.S. is diagnosed with diffuse intrinsic pontine glioma; the most common age at detection is 63 and most common signs are nonspecific headache and vomiting. The incidence of diffuse intrinsic pontine glioma has increased markedly in recent years in the U.S. This report highlights the importance of further studies to identify the most common genetic drivers of diffuse intrinsic pontine gliomas, the role of the "one-hit" hypothesis, and the impact of radiation exposure on the risk of diffuse intrinsic pontine glioma a decade after childhood brain cancer diagnosis." - Anonymous Online Contributor
"DIPG affects younger patients and those with a family history of cancer. Both sexes and blacks have a greater risk of DIPG relative to whites and Asians, which is associated with an earlier age of diagnosis. Diagnosis of DIPG is difficult because of its clinical similarity to other brain tumors. For this reason, some clinicians question whether diagnosis-appropriate treatment is being provided to these patients." - Anonymous Online Contributor
"DIPG was one of the most common primary brain tumors in western Canada, Alberta, occurring primarily in men in an age that mirrored that of its western counterparts. Further work to investigate epidemiology and risk factors for DIPG in different cultures is needed in order to prevent and treat this condition." - Anonymous Online Contributor
"A small proportion of PGGs present without any history of seizure. Seizures are the most common signs in PGG. In pediatric and adult population, PGG is a rare differential diagnosis for focal seizures including focal cortical dysplasia, infarction, or metastasis. High grade dysplasia and medulloblastomas have similar patterns of brainstem compression and are common differential diagnoses along with PGG in children as well as adults. PGG in any age group usually presents with signs and symptoms of headache and a focal neurologic exam. PGG should be considered if focal neurologic symptoms occur in association with acute onset hemiparesis or hemiplegia." - Anonymous Online Contributor
"A variety of treatments exist for diffuse intrinsic pontine gliomas. These include radiation therapy, surgical resection, chemotherapy, targeted therapy that includes monoclonal antibodies and immunotherapy, and gene therapy." - Anonymous Online Contributor
"It is likely that most patients with diffuse intrinsic pontine gliomas that initially present as a low grade glioma will eventually relapse. However, the time to relapse seems to be a critical and independent factor in survival prognosis when diffuse intrinsic pontine gliomas are initially diagnosed within the pediatric set up. This can make diffuse intrinsic pontine gliomas a better indication for surgery than glioblastomas or medulloblastoma in the pediatric patient population. In those cases of relapse, it is possible to treat with a combination of surgery and radiation." - Anonymous Online Contributor
"There has not been a single clinical trial investigating the efficacy of adavosertib. The role of adavosertib requires clarification before it can be placed into the first-line therapy. Future randomized phase III studies and/or new clinical trial data on patients with low-grade gliomas should be conducted." - Anonymous Online Contributor
"DSIPG is very, very serious. Only 5/8 of patients who are diagnosed with DSIPG survive for more than 1 year after diagnosis. No factors are associated with a longer overall survival in patients with DSIPG." - Anonymous Online Contributor
"The presence of DTIPGs in families of probands with these tumors suggests that a common molecular pathway might be involved. Further elucidation of the mechanism or pathways by which these tumors develop might result in the identification of a target for rational intervention." - Anonymous Online Contributor
"ADV in DIPG patients showed an improvement in PFS and OS versus a placebo, with significant differences in OS and PFS at 8 weeks, suggesting that ADV should be further studied in DIPG patients as a treatment option." - Anonymous Online Contributor
"By inhibiting MAP1 kinase pathway, both in vitro and in vivo, AD may exert its therapeutic effects by preventing cell proliferation and differentiation, and inducing apoptosis. These features are shared with other MAP1 kinase pathway inhibitors, which suggests that AD may be a promising candidate for the treatment of DIPG." - Anonymous Online Contributor
"The average age at diagnosis of diffuse intrinsic pontine [oligodendroglioma](https://www.withpower.com/clinical-trials/oligodendroglioma) was 68 years, but it is rare among patients younger than 50 years. Results from a recent clinical trial imply that diffuse intrinsic pontine gliomas have a slower growth rate than oligodendrogliomas, particularly among patients younger than 50 years. The incidence of diffuse intrinsic pontine glioma is expected to increase by 6% for each year after age 50 years, reaching 27,000 by 2040. The incidence of other central nervous system tumors has increased significantly." - Anonymous Online Contributor